WisdomTree BioRevolution Fund (WDNA)
| Assets | n/a |
| NAV | n/a |
| Expense Ratio | n/a |
| PE Ratio | n/a |
| Shares Out | n/a |
| Dividend (ttm) | $0.02 |
| Dividend Yield | 0.14% |
| Ex-Dividend Date | n/a |
| 1-Year Return | -33.98% |
| Volume | 423 |
| Open | 17.51 |
| Previous Close | 17.07 |
| Day's Range | 17.07 - 17.59 |
| 52-Week Low | 15.94 |
| 52-Week High | 26.60 |
| Beta | n/a |
| Holdings | n/a |
| Inception Date | Jun 3, 2021 |
About WDNA
The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the Index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.
News
Biden's “Cancer Moonshot” Brings Biotech Focus Back to U.S.
President Biden spoke at the Kennedy Presidential Library on the 60th anniversary of JFK's moonshot speech on Monday, September 12, outlining his plans for building out American research to end cancer, ...
When Megatrends Intersect, Investors Can Benefit
When it comes to disruptive growth concepts, also known as megatrends, investors frequently focus on these technologies in singular fashion. However, one of the more alluring factors in innovative growt...
Rare Valuation Opportunities Afoot in Some Megatrends ETFs
Equities are off to a dismal start to 2022, with high-growth and technology stocks, particularly shares of unprofitable companies, ranking among the worst offenders.
Top ETFs Tracking CRISPR Gene Editing
These ETFs give you exposure to CRISPR gene editing without having to pick individual stocks.
Harness Power, Promise of Genetics Research with WDNA
Genomics represents one of the most disruptive, opportunity-rich investment frontiers, but stock picking in this space is tricky, to say the least. That underscores the utility of various genomics-dedic...
Historic Opportunity Afoot in Biotech Investing
Some market pundits love clarion calls and hyperbole, but there are times when credibly rare opportunities do emerge. That might be happening today with biotech, genomics, and other next-generation heal...
As New Healthcare Era Dawns, Consider WDNA
Investors looking for sector-level innovation beyond the technology realm don't need to stretch into unfamiliar territory — healthcare is prime territory for disruptive growth concepts. Several exchange...
All Aboard for the BioRevolution!
By Jamie Metzl & Jeremy Schwartz, WisdomTree Discussing the investing opportunity of one of the 21st century's defining megatrends WisdomTree has collaborated with Dr. Jamie Metzl to help create the Wi...
Embrace WDNA as BioRevolution Gains Momentum
Investors looking for innovative companies and disruptive growth opportunities without excessive exposure to the technology sector would do well to check out healthcare. Arguably, healthcare is the most...
The WDNA ETF: Investing in Healthcare Innovation
As has been widely noted over the past 18 months, the coronavirus pandemic has accelerated dramatic shifts in a myriad of sectors and industries. One of the obvious members of that group is healthcare.
The BioRevolution: An ETF That Taps Into Nearly Everything
Exchange traded fund investors should consider the current opportunities in healthcare innovation. In the recent webcast, The Era of Biotech: How Biology Became Technology, Jeremy Schwartz, Executive Vi...
The Era of Biotech: How Biology Became Technology
First was the industrial revolution, then came the information era with the Internet; next up are genetics and biotechnology. New megatrends help steer the way the global economy develops.